Ulrik Niels Lassen
Clinical Professor
- Published
18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)
Lassen, Ulrik Niels, Daugaard, G., Eigtved, A., Damgaard, K. & Friberg, L., Jul 1999, In: European journal of cancer (Oxford, England : 1990). 35, 7, p. 1076-82 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma
Nedergaard, M. K., Michaelsen, Signe Regner, Urup, T., Broholm, H., El Ali, Henrik H., Poulsen, H. S., Stockhausen, M., Kjær, Andreas & Lassen, Ulrik Niels, 2015, In: P L o S One. 10, 2, p. 1-16 16 p., e0115315.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A Comparison of Endoscopic Ultrasound Guided Biopsy and Positron Emission Tomography with Integrated Computed Tomography in Lung Cancer Staging
Larsen, S. S., Vilmann, Peter, Krasnik, K., Dirksen, A., Clementsen, P., Skov, B. G., Jacobsen, G. K., Lassen, Ulrik Niels, Eigtved, A., Berthelsen, A. K., Mortensen, J. & Højgaard, Liselotte, Jan 2009, In: Current Health Sciences Journal. 35, 1, p. 5-12 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas
Lassen, Ulrik Niels, Jensen, L. H., Sorensen, M., Rohrberg, K. S., Ujmajuridze, Z. & Jakobsen, A., 1 Apr 2011, In: Acta Oncologica. 50, 3, p. 448-54 7 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
de Weger, V. A., Goel, S., von Moos, R., Schellens, J. H. M., Mach, N., Tan, E., Anand, S., Scott, J. W. & Lassen, Ulrik Niels, 2018, In: Cancer Chemotherapy and Pharmacology. 81, 1, p. 73-80 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers
Lassen, Ulrik Niels, Meulendijks, D., Siu, L. L., Karanikas, V., Mau-Sorensen, M., Schellens, J. H. M., Jonker, D. J., Hansen, A. R., Simcox, M. E., Schostack, K. J., Bottino, D., Zhong, H., Roessler, M., Vega-Harring, S. M., Jarutat, T., Geho, D., Wang, K., DeMario, M. & Goss, G. D., 15 Jan 2015, In: Clinical Cancer Research. 21, 2, p. 258-66 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer
Holländer, C., Baeksgaard, L., Sorensen, M., Albertsson, P., Damstrup, L. & Lassen, Ulrik Niels, Sep 2012, In: Anticancer Research. 32, 9, p. 4019-23 5 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
Mirza, M. R., Bergmann, T. K., Mau-Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E., Birrer, M. J., Jørgensen, M., Roed, H., Malander, S., Nielsen, F., Lassen, Ulrik Niels, Brøsen, K., Bjørge, L. & Mäenpää, J., 2019, In: Cancer Chemotherapy and Pharmacology. 84, 4, p. 791-798 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
Lassen, Ulrik Niels, Molife, L. R., Sorensen, J. M., Engelholm, S., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P., de Bono, J. S. & Buhl-Jensen, P., 29 Jun 2010, In: B J C. 103, 1, p. 12-7 6 p.Research output: Contribution to journal › Journal article › Research › peer-review
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3
Mau-Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, Ulrik Niels, Büchler, W., Martinius, H. & Tabernero, J., May 2015, In: Cancer Chemotherapy and Pharmacology. 75, 5, p. 1065-73 9 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 4952653
Most downloads
-
479
downloads
Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
224
downloads
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
174
downloads
Hallmarks of glioblastoma: a systematic review
Research output: Contribution to journal › Review › Research › peer-review
Published